CHRM2 and glioblastoma: These results clearly suggest that N-8-Iper has a more potent action on GSCs than APE, thus making this dual-acting agonist a promising muscarinic ligand able to better characterize the inhibitory effects of the M2 muscarinic receptor in glioblastoma cells as well as in other tumor types.